Chalay mida
"Chalay mida" is a Gujarati/Hindi informal phrase that roughly translates to "Let's go" or "Come on, let's get moving" in English. It's a casual, encouraging expression used to prompt someone to start or get going.
Is there something specific you'd like help with today? 😊
Dm 2
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
I now have enough information from Harrison's for a comprehensive answer. Let me compile it.
Type 2 Diabetes Mellitus (DM2)
Definition
Type 2 DM is a chronic metabolic disorder characterized by hyperglycemia arising from a combination of insulin resistance and impaired insulin secretion. Most evidence suggests insulin resistance precedes the secretory defect, but DM develops only when insulin secretion becomes inadequate for the degree of resistance.
- Harrison's Principles of Internal Medicine 22E, p. 3244
Pathophysiology
The five core defects are:
| Defect | Details |
|---|---|
| Impaired insulin secretion | Beta cell dysfunction, progressive over years |
| Insulin resistance | Mainly in skeletal muscle, liver, and adipose |
| Excess hepatic glucose output | Fasting hyperglycemia driven by unrestrained gluconeogenesis |
| Abnormal fat metabolism | Elevated FFAs, lipotoxicity |
| Systemic low-grade inflammation | Promotes further insulin resistance |
- Obesity (especially visceral/central) is present in ≥80% of patients
- In the early stages, glucose tolerance is relatively preserved because the pancreas compensates with hyperinsulinemia
- Over time, beta cell "exhaustion" leads to overt hyperglycemia
- Ethnic variation: Latinos tend toward insulin resistance; East/South Asians toward beta cell dysfunction - both develop DM2 at a younger age and lower BMI
Genetics
- Concordance in identical twins: 70-90% (strong genetic component)
- Polygenic (>600 susceptibility loci identified via GWAS)
- Most prominent: variant in TCF7L2 (transcription factor 7-like 2 gene)
- If both parents have DM2, the offspring risk approaches 70%
- The in-utero environment also plays a role: both high and low birth weight raise adult DM2 risk
Diagnosis
The ADA diagnostic criteria (any one of the following):
| Criterion | Value |
|---|---|
| Fasting plasma glucose (FPG) | ≥126 mg/dL (7.0 mmol/L) |
| 2-hour plasma glucose (75g OGTT) | ≥200 mg/dL (11.1 mmol/L) |
| HbA1c | ≥6.5% (48 mmol/mol) |
| Random glucose with symptoms | ≥200 mg/dL |
Prediabetes: FPG 100-125 mg/dL, or HbA1c 5.7-6.4%, or 2h glucose 140-199 mg/dL.
Screening labs should also include: albuminuria, lipid panel, thyroid function, C-peptide (if DM type unclear), islet cell antibodies.
Clinical Features of DM2 vs DM1
| Feature | DM2 | DM1 |
|---|---|---|
| Age of onset | Usually >40, but rising in youth | Usually <35 |
| Body habitus | Obese (80%) | Usually non-obese |
| Onset | Gradual | Acute (polyuria, DKA) |
| Insulin at diagnosis | Not usually required | Required |
| Islet antibodies (GAD, ICA) | Absent | Present |
| Associations | HTN, dyslipidemia, PCOS, ASCVD | Other autoimmune diseases |
Management
Non-pharmacologic (First Line for All Patients)
- Medical Nutrition Therapy (MNT): caloric restriction, carbohydrate awareness
- Exercise: improves insulin sensitivity, promotes weight loss
- Weight loss of 5-10% significantly improves glycemic control
Pharmacologic Agents
| Class | Example | Mechanism | Key Notes |
|---|---|---|---|
| Biguanides | Metformin | Reduces hepatic glucose output | First-line; weight neutral; avoid if GFR <30, liver disease, acidosis, contrast |
| Sulfonylureas | Glipizide, Glimepiride | Stimulate insulin secretion (K+ATP channel) | Risk of hypoglycemia + weight gain; avoid in renal/hepatic impairment |
| GLP-1 RAs | Semaglutide, Dulaglutide, Liraglutide | Glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying | Weight loss; reduces cardiovascular events in ASCVD; weekly dosing |
| SGLT-2 Inhibitors | Empagliflozin, Dapagliflozin | Promote urinary glucose excretion | Cardioprotective + nephroprotective; risk of genital mycotic infections, DKA |
| DPP-4 Inhibitors | Sitagliptin | Enhance endogenous GLP-1 | Weight neutral; well tolerated; renal dose adjustment needed |
| Thiazolidinediones (TZDs) | Pioglitazone | Insulin sensitizer (PPAR-γ agonist) | Weight gain, fluid retention, bone loss; avoid in CHF |
| Alpha-glucosidase inhibitors | Acarbose | Delay carb absorption | GI side effects; modest efficacy |
| Insulin | Multiple types | Replaces deficient insulin | Used when oral agents fail or in severe hyperglycemia |
Key priority principles (Harrison's, 2025):
- Cardiovascular risk reduction is the most important goal - DM2's #1 cause of mortality is ASCVD
- Choose GLP-1 RA or SGLT-2 inhibitor in patients with established ASCVD, HF, or CKD (benefit beyond glucose lowering)
- DM2 is progressive - most patients will eventually need multiple agents or insulin
Complications
Microvascular
- Retinopathy - most common cause of blindness in working-age adults
- Nephropathy (Diabetic Kidney Disease) - leading cause of ESRD
- Neuropathy - peripheral, autonomic
Macrovascular
- CAD, MI - leading cause of death
- Stroke
- Peripheral artery disease (PAD)
Acute Metabolic
- Hyperosmolar Hyperglycemic State (HHS) - more common in DM2 than DKA
- Hypoglycemia (from treatment)
- DKA - can occur in ketosis-prone DM2 (especially in African Americans)
Glycemic Targets (ADA, individualized)
| Parameter | General Target |
|---|---|
| HbA1c | <7% (individualized; may be <8% in elderly/frail) |
| Fasting glucose | 80-130 mg/dL |
| Peak postprandial glucose | <180 mg/dL |
| BP | <130/80 mmHg |
| LDL-C | <70 mg/dL (with ASCVD) |
Sources: Harrison's Principles of Internal Medicine 22E (2025), pp. 3244-3256 | Katzung's Basic and Clinical Pharmacology, 16th Ed. | Basic Medical Biochemistry, 6th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.